NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
06/23/2026
Back to search
Official data from USPTO
IMMUNESENSOR THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
IMMUNESENSOR THERAPEUTICS
ST13
US500000088267263Class
42
Filing
88267263
Registration
6031149
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
37
Latest update
06/24/2026
Trademark type
Word
Nice classes
42
Filing date
01/18/2019
Registration date
04/07/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/23/2026
Last transaction
06/24/2026
Responsible office
United States Patent and Trademark Office
Status code
701
Official register
Supplemental Register
Filing basis
Intent to use
First use anywhere
2019-06-00
First use in commerce
2019-06-00
Drawing code
4
Owner type
03
Owner location
DALLAS, TX, US
Examiner
SINGLETON, RUDY
Current location
Historical data usage
Holders and representatives
Holders
IMMUNESENSOR THERAPEUTICS, INC.
Immune Sensor, LLC
Representatives
Christopher M. Kindel PIRKEY BARBER PLLC
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Biotechnology researchresearch and development of pharmaceutical preparations for use in humans; Medical research; Research and development of pharmaceutical preparations for the treatment of cancer and immunological diseases; Providing medical and scientific research information in the fields of pharmaceuticalsbiologicalsclinical trials
Publications
History of USPTO decisions and trademark events.
37 publications found
8.OK
REGISTERED - SEC. 8 (6-YR) ACCEPTED
06/23/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
06/23/2026
ES8R
TEAS SECTION 8 RECEIVED
03/11/2026
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
04/07/2025
R.SR
REGISTERED-SUPPLEMENTAL REGISTER
04/07/2020
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
03/03/2020
AAUA
NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
03/03/2020
CNTA
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
02/29/2020
IUAA
USE AMENDMENT ACCEPTED
02/29/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/24/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/24/2020
AUPC
AMENDMENT TO USE PROCESSING COMPLETE
02/21/2020
IUAF
USE AMENDMENT FILED
02/21/2020
EAAU
TEAS AMENDMENT OF USE RECEIVED
02/21/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/21/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/21/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/21/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02/21/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
02/21/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/21/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/01/2019
GNRT
NON-FINAL ACTION E-MAILED
11/01/2019
CNRT
NON-FINAL ACTION WRITTEN
11/01/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/03/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/03/2019
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/03/2019
ALIE
ASSIGNED TO LIE
10/03/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/25/2019
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/19/2019
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
07/17/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/31/2019
GNRT
NON-FINAL ACTION E-MAILED
03/31/2019
CNRT
NON-FINAL ACTION WRITTEN
03/31/2019
DOCK
ASSIGNED TO EXAMINER
03/31/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/10/2019
NWAP
NEW APPLICATION ENTERED
01/22/2019
Continuous trademark protection
Get notified about every new filing that threatens IMMUNESENSOR THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.